Cerenovus, part of Johnson & Johnson MedTech, has today announced the launch of its Cereglide 71 aspiration catheter in Europe, an aspiration catheter equipped with TruCourse technology, indicated for the revascularisation of patients suffering from acute ischaemic stroke.
The Cereglide 71 aspiration catheter is the latest innovation in a planned Cereglide family of catheters to join the Cerenovus stroke solutions portfolio. Cereglide 71 is optimised for effective, direct aspiration of blood clots and for the delivery of compatible stent retrievers, including the Embotrap III revascularisation device and Cerenovus’ Nimbus geometric clot extractor, into the neurovasculature.
“The introduction of the Cereglide 71 aspiration catheter in Europe is an important step in endovascular thrombectomy, as it allows swift, targeted clot access and removal during stroke treatment,” said Kyriakos Lobotesis (Imperial College London, London, UK). “With Cereglide 71 aspiration catheter, we can now access occlusion sites and aspirate clots more rapidly and efficiently, maintaining a smooth interaction with stent retrievers when used in co-aspiration. This leads to the prompt restoration of blood flow in the patient’s brain, which has the potential to save more lives and improve long-term clinical outcomes.”
As stated in a Cerenovus press release, in up to nearly 50% of stroke thrombectomy cases, challenging anatomical features are present that can impact access to the clot, procedure time, recanalisation success, and clinical outcomes.
The TruCourse technology used in the Cereglide 71 aspiration catheter increases flexibility of the device, which is designed to deliver smoother navigation and access to clots, even in challenging anatomical conditions, Cerenovus claims, adding that this provides physicians with optimal compatibility, durable delivery, and reliable trackability, during thrombectomy procedures.
“The Cereglide 71 aspiration catheter using TruCourse technology represents a great advancement in acute ischaemic stroke treatment,” said Mark Dickinson, worldwide president, Cerenovus. “It provides physicians with a greater level of flexibility while offering reliable trackability, durable delivery, and versatility, for both direct aspiration and stent-retriever use.”
Devices within the Cerenovus stoke solutions portfolio are developed using Cerenovus’ stroke science insights from its Neuro Thromboembolic Initiative (NTI). The results, according to the company, are products that have been tested in models that simulate real-world scenarios and seek to further address unmet clinical needs. The Cereglide 71 aspiration catheter will be included in the next phase of Cerenovus’ EXCELLENT registry, a real-world registry focused on studying stroke-inducing blood clot removal by mechanical thrombectomy.
